KEYNOTE-010 Shows Overall Survival Benefit of Pembrolizumab in NSCLC

Video

Roy. S. Herbst, MD, PhD, professor of Medicine (Medical Oncology), professor of Pharmacology, chief of Medical Oncology, Yale Cancer Center, discusses the phase III KEYNOTE-010 study, in which pembrolizumab provided superior overall survival over docetaxel in patients with previously treated, PD-L1-expressing advanced non-small cell lung cancer. He discussed these results during an interview at the IASLC 17th World Conference on Lung Cancer.

Related Videos
Related Content